Helmut Wolfgang Jeggle - 02 Nov 2026 Form 4 Insider Report for Bambusa Therapeutics, Inc.

SEC form
4
Accepted by SEC
02 Nov 2026, 16:06:10 UTC
Prior SEC filing
29 Oct 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Helmut Wolfgang Jeggle filed Form 4 for Bambusa Therapeutics, Inc. on 02 Nov 2026.

Key facts

  • This page summarizes Helmut Wolfgang Jeggle's Form 4 filing for Bambusa Therapeutics, Inc..
  • 5 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 02 Nov 2026, 16:06.

Change

  • Previous filing in this sequence was filed on 29 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001982614 Primary reporting owner

Jeggle Helmut Wolfgang

Relationship
Director, 10%+ Owner

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,769,701
Change %
+116%
Price
Shares after
8,889,301
Date
02 Nov 2026
Ownership
See footnote
Footnotes
F1, F2
No ticker transaction

Common Stock

Purchase

Transaction value
Shares
+375,000
Change %
+4.2%
Price
$16.00*
Shares after
9,264,301
Date
02 Nov 2026
Ownership
See footnote
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Series Seed Plus Preferred Stock

Conversion of derivative security

Transaction value
Shares
-3,135,066
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
3,135,066
Exercise price
Footnotes
F1, F2
No ticker transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-1,473,775
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
1,473,775
Exercise price
Footnotes
F1, F2
No ticker transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares
-160,860
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
160,860
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

Footnote F2

Shares held by Salvia Investment GmbH ("Salvia"). The Reporting Person is the Managing Director of Salvia GmbH and has sole voting and dispositive power with respect to the shares held by Salvia. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .